Impacts of triglyceride-glucose index on prognosis of patients with type 2 diabetes mellitus and non-ST-segment elevation acute coronary syndrome: results from an observational cohort study in China

Table 6 Predictive value of TyG index for primary endpoint and each component in univariate and multivariate analysis

	Univariate analysis			Multivariate analysis^c
	HR	95% CI	P value	HR	95% CI	P value
TyG index as a nominal variable^a
Primary endpoint	4.610	3.253–6.533	< 0.001	4.062	2.732–6.040	< 0.001
All-cause death	2.103	0.705–6.276	0.183	0.872	0.179–4.258	0.866
Non-fatal MI	3.744	1.767–7.935	0.001	2.260	0.894–5.715	0.085
Ischemia-driven revascularization	4.920	3.218–7.521	< 0.001	4.980	3.075–8.067	< 0.001
TyG index as a continuous variable^b
Primary endpoint	3.367	2.677–4.235	< 0.001	3.208	2.400–4.289	< 0.001
All-cause death	1.358	0.610–3.024	0.454	0.429	0.111–1.659	0.220
Non-fatal MI	4.449	2.684–7.373	< 0.001	3.332	1.730–6.415	< 0.001
Ischemia-driven revascularization	2.874	2.216–3.727	< 0.001	3.021	2.167–4.211	< 0.001

Italic values indicate statistically significant associations
TyG triglyceride glucose, MI myocardial infarction, HR hazard ratio, CI confidence interval
^aThe HR was examined regarding lower TyG index as reference (stratified by the optimal cutoff point of TyG index determined by ROC curve analysis)
^bThe HR was examined by per 1-unit increase of TyG index
^cThe multivariate analysis was performed by using Model 4 [adjusted for age, sex (female), BMI, SBP, DBP, smoking, drinking, duration of diabetes, dyslipidemia, prior MI, PCI, stroke, PVD, diagnosis (NSTEMI), TC, HDL-C, eGFR, HbA1c, LVEF, SYNTAX score, LM treatment, DCB use, complete revascularization, number of stents, DAPT at discharge, DAPT interruption in 12 months, statins at discharge, statins interruption in 12 months, oral hypoglycemic agents (metformin, alpha-glucosidase inhibitor, sulfonylurea, dipeptidyl peptidase 4 inhibitor) at discharge and insulin at discharge]

ISSN: 1475-2840